Compare Qurate Retail Inc Series A (QVCAQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Qurate Retail Inc Series A vs Vertex Pharmaceuticals Incorporated — how do they compare? Qurate Retail Inc Series A trades at $0.04 (market cap $653.75K), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 187120.5× Qurate Retail Inc Series A's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| QVCAQ | VRTX | |
|---|---|---|
Market Cap | $653.75K | $122.33B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.03 | $529.59 |
52-Week Low | $0.05 | $366.54 |
Enterprise Value | $4.73B | $117.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QVCAQ trades at $0.0515, down 12.12% in the past 24 hours, with a bearish technical signal from moving averages. The company reported a net loss of $2.44 billion in 2025 on revenue of $9.23 billion, with negative profit margins and declining revenue trends. Cash flow improved due to financing activities, but negative equity and high debt-to-asset ratios of 77.57% highlight financial stress. Recent news includes QVC celebrating 40 years of live shopping innovation with a TikTok Shop Super Brand Day (PRNewsWire, May 28, 2026).
The outlook remains challenging due to persistent losses, high leverage, and revenue declines. Investment opportunities are limited given weak fundamentals, though low P/E and P/B ratios may attract value hunters. Key risks include bankruptcy concerns from negative equity, competitive pressures in retail, and inability to achieve profitability. Analyst sentiment is cautious, with no bullish indicators supporting near-term recovery.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
